Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Wood Group finds 'material weakness and failures' in accounts

(Sharecast News) - Engineering and consulting business Wood Group revealed on Monday that its shares would most likely be suspended from trading on the London Stock Exchange after finding "material weakness and failures" in its books. Wood Group said it had uncovered failings due to "inappropriate management pressure", including instances of management overriding financial reporting to maintain previously reported positions through "unsupported dispensations and over-optimism and/or lack of evidence in respect of accounting judgements".

The FTSE 100-listed group said an initial review called for "material" prior-year adjustments to both its profit and loss and balance sheets for FY22 and FY23, as well as H124.

Wood stated that adjusted underlying earnings and EBIT were likely to be restated, with the changes principally impacting historical reported performance in its projects unit. Issues were primarily related to legacy lump sum turnkey contracts and the misapplication of accounting standards.

Wood now to publish its FY24 numbers by 30 April, meaning it would miss the London Stock Exchange's four-month deadline and lead to its shares being suspended.

"We are committed to implementing a detailed remediation plan, including necessary follow-on actions from the review, to continue to strengthen the group's financial culture, governance and controls. This will include actions on culture, controls and organisational structure," said Wood.

As of 0900 BST, Wood Group shares were down 27.94% at 28.78p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.